Breast
Featured Articles
(PharmaTimes [UK]) July 17, 2019 - NICE has recommended Novartis’ Kisqali just three months after its initial rejection. The National Institute of Health and Care Excellence (NICE) has recommended Novartis’ Kisqali (ribociclib) for use on the NHS in combination with fulvestrant, where exemestane plus everolimus is the most...
Read Article
(Reuters) July 11, 2019 - People who drink a lot of sugary drinks have a higher risk of developing cancer, although the evidence cannot establish a direct causal link, researchers said on Thursday. The findings of a large study in France do suggest, however, that limiting intake of sugar-sweetened drinks may help to cut the number of...
Read Article
Latest Articles
July 19, 2019
July 19, 2019
July 18, 2019
July 17, 2019
July 17, 2019
July 15, 2019
July 12, 2019
July 11, 2019
View More
News Commentary
Editor Image
30 May, 2019 | by Debu Tripathy, MD
The PI3 kinase pathway is difficult to target as it is the superhighway to...
View Comment
Editor Image
17 May, 2019 | by
Trastuzumab deruxtecan makes Margetixumab clinically irrelevant
View Comment
View More
OBR Blog
Several late-breaking studies made a splash today at the 2019 American Society of Clinical Oncology (ASCO) Annual... Read more
June 01, 2019
One of biggest challenges in attending an annual ASCO meeting is time management. With over 2,000 abstracts submitted... Read more
May 29, 2019